2.60

1.17% 0.03

After Hours: 2.60

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.60, with a volume of 621.97K. It is up +1.17% in the last 24 hours and down -2.62% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Previous Close:

$2.57

Open:

$2.57

24h Volume:

621.97K

Relative Volume:

0.53

Market Cap:

$148.13M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-1.383

EPS:

-1.88

Net Cash Flow:

$-66.75M

1W Performance:

+4.42%

1M Performance:

-2.62%

6M Performance:

+0.78%

1Y Performance:

+22.07%

1-Day Range:

$2.525

$2.615

1-Week Range:

$2.41

$2.615

52-Week Range:

$1.195

$4.94

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

617-417-5868

Address

ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	2.60	146.43M	0	-82.44M	-66.75M	-1.88
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Downgrade	Guggenheim	Buy → Neutral
Nov-18-25	Resumed	Piper Sandler	Overweight
Oct-16-25	Resumed	Stifel	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Jul-01-25	Resumed	Raymond James	Outperform
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Jan 03, 2026

Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo

Jan 03, 2026

Black Diamond Therapeutics’ Silevertinib shows 60% response rate in preliminary phase 2 lung cancer data - MSN

Jan 03, 2026

Jan 02, 2026

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Jan 02, 2026

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jan 02, 2026

Dec 31, 2025

Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Insider Monkey

Dec 31, 2025

Dec 27, 2025

What analysts say about Black Diamond Therapeutics Inc stockCandlestick Trading Patterns & High Return Trading Ideas - earlytimes.in

Dec 27, 2025

Dec 22, 2025

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to NASDAQ Biotechnology Index - marketscreener.com

Dec 22, 2025

Why Black Diamond Therapeutics Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Based Buy/Sell Signal Reports - Улправда

Dec 22, 2025

Dec 21, 2025

BDTX (Black Diamond Therapeutics) EV-to-OCF : 1.30 (As of Dec. 21, 2025) - GuruFocus

Dec 21, 2025

Dec 19, 2025

Can Black Diamond Therapeutics Inc. stock deliver strong Q4 earnings2025 Institutional Moves & Daily Market Momentum Tracking - DonanımHaber

Dec 19, 2025

What margin trends mean for Black Diamond Therapeutics Inc. stockMarket Performance Recap & Verified Short-Term Trading Plans - DonanımHaber

Dec 19, 2025

Can Black Diamond Therapeutics Inc. stock withstand economic slowdown2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда

Dec 19, 2025

Dec 18, 2025

What momentum indicators show for Black Diamond Therapeutics Inc. stockWeekly Stock Summary & Accurate Trade Setup Notifications - Улправда

Dec 18, 2025

Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail

Dec 18, 2025

Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail

Dec 18, 2025

Dec 15, 2025

Black Diamond Therapeutics (BDTX) director receives 4,665 share award - Stock Titan

Dec 15, 2025

Dec 10, 2025

Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates - Defense World

Dec 10, 2025

Dec 09, 2025

A strong week for data readouts: Clinical Report - BioCentury

Dec 09, 2025

Dec 05, 2025

Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance

Dec 05, 2025

Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - sharewise.com

Dec 05, 2025

Can Black Diamond Therapeutics Inc. stock continue upward trendGap Down & Long-Term Investment Growth Plans - Newser

Dec 05, 2025

Will Black Diamond Therapeutics Inc. stock attract more institutional investorsInsider Selling & Technical Pattern Based Buy Signals - Newser

Dec 05, 2025

Dec 04, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim - MarketBeat

Dec 04, 2025

Stifel reiterates Buy rating on Black Diamond Therapeutics stock at $8 - Investing.com Australia

Dec 04, 2025

Analyst Downgrades BDTX to Neutral from Buy | BDTX Stock News - GuruFocus

Dec 04, 2025

This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Dec 04, 2025

How Black Diamond Therapeutics Inc. stock reacts to oil pricesBond Market & Consistent Profit Trade Alerts - Newser

Dec 04, 2025

Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded by Guggenheim to Neutral - Defense World

Dec 04, 2025

Dec 03, 2025

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Sahm

Dec 03, 2025

Are Smart Investors Making the Right Decision? Black Diamond Therapeutics Inc (BDTX) - Setenews

Dec 03, 2025

US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - Benzinga

Dec 03, 2025

Black Diamond Therapeutics announces preliminary Phase 2 data for Silevertinib in 1L NSCLC - marketscreener.com

Dec 03, 2025

Black Diamond Therapeutics (BDTX) Reveals Promising Phase 2 Tria - GuruFocus

Dec 03, 2025

Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire

Dec 03, 2025

Black Diamond to present Phase 2 silevertinib trial results By Investing.com - Investing.com Canada

Dec 03, 2025

Dec 02, 2025

Black Diamond to present Phase 2 silevertinib trial results - Investing.com India

Dec 02, 2025

Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative

Dec 02, 2025

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times

Dec 02, 2025

Black Diamond Therapeutics to Host Webcast Presentation - GlobeNewswire

Dec 02, 2025